Eligibility criteria for pediatric patients who may benefit from anti SARS-CoV-2 monoclonal antibody therapy administration: an Italian inter-society consensus statement
Open Access
- 12 January 2022
- journal article
- review article
- Published by Springer Science and Business Media LLC in Italian Journal of Pediatrics
- Vol. 48 (1), 1-10
- https://doi.org/10.1186/s13052-021-01187-1
Abstract
The fast diffusion of the SARS-CoV-2 pandemic have called for an equally rapid evolution of the therapeutic options. The Human recombinant monoclonal antibodies (mAbs) have recently been approved by the Food and Drug Administration (FDA) and by the Italian Medicines Agency (AIFA) in subjects aged ≥12 with SARS-CoV-2 infection and specific risk factors. Currently the indications are specific for the use of two different mAbs combination: Bamlanivimab+Etesevimab (produced by Eli Lilly) and Casirivimab+Imdevimab (produced by Regeneron). These drugs have shown favorable effects in adult patients in the initial phase of infection, whereas to date few data are available on their use in children. AIFA criteria derived from the existing literature which reports an increased risk of severe COVID-19 in children with comorbidities. However, the studies analyzing the determinants for progression to severe disease are mainly monocentric, with limited numbers and reporting mostly generic risk categories. Thus, the Italian Society of Pediatrics invited its affiliated Scientific Societies to produce a Consensus document based on the revision of the criteria proposed by AIFA in light of the most recent literature and experts’ agreement. This Consensus tries to detail which patients actually have the risk to develop severe disease, analyzing the most common comorbidities in children, in order to detail the indications for mAbs administration and to guide the clinicians in identifying eligible patients.Keywords
This publication has 69 references indexed in Scilit:
- Prognosis of patients with sickle cell disease and COVID-19: a French experienceThe Lancet Haematology, 2020
- Coronavirus Disease 2019 (COVID‐19) Pandemic Implications in Pediatric and Adult Congenital Heart DiseaseJournal of the American Heart Association, 2020
- Severe and fatal forms of COVID-19 in childrenArchives de Pédiatrie, 2020
- Health status of patients with autoimmune liver disease during SARS-CoV-2 outbreak in northern ItalyJournal of Hepatology, 2020
- COVID19: potential cardiovascular issues in pediatric patients.2020
- COVID-19 in people living with human immunodeficiency virus: a case series of 33 patientsInfection, 2020
- COVID‐19 infection and sickle cell disease: a UK centre experienceBritish Journal of Haematology, 2020
- How is immunosuppressive status affecting children and adults in SARS-CoV-2 infection? A systematic reviewJournal of Infection, 2020
- Risk factors for pulmonary hypertension in patients with β thalassemia intermediaEuropean Journal of Internal Medicine, 2011
- β‐Thalassaemia and sickle cell anaemia as paradigms of hypercoagulabilityBritish Journal of Haematology, 2007